This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com
Dallas, TX (PRWEB) January 01, 2013
The prescription drug resource center DrugRisk.com has added information to its already comprehensive online database showing use of the birth control drugs Yaz and Yasmin may be increasing, despite warnings about blood clot risks and the settlement of thousands of injury claims by Bayer.
“DrugRisk seeks to improve public safety by providing the latest prescription drug warnings, recalls, studies and litigation news. We were surprised to learn that more people used Yaz in 2012 than 2011 despite all the warnings and injury settlements,” said DrugRisk representative Ryan Mayer.
The news, from the Healthcare Business Development section of the latest financial report from Bayer, indicates the company sold $277 million worth of Yaz and Yasmin in the third quarter of 2012 versus $275 million in 2011.*
The resource center had previously advised of new warnings by the American College of Obstetricians and Gynecologists that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.**
DrugRisk has learned that Yaz lawsuits are being consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
According to Bayer, they have already settled approximately 3,500 Yaz lawsuits for a total cost of nearly $750 million, or an average of $214,000 per case.*** The company confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
**Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
***Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebyaz-recall/yaz-lawsuits/prweb10282897.htm